STOCK TITAN
  1. Home
  2. News
  3. TRVN

Trevena to Present at the Virtual JMP Securities CNS Forum

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

CHESTERBROOK, Pa., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President and Chief Executive Officer, will participate in a fireside chat at the JMP Securities CNS Forum, being held virtually on August 19 - 20, 2020.

Presentation Details

Date: Thursday, August 20, 2020
Time:  12:30 p.m. Eastern Time
Webcast: https://www.trevena.com/investors/events-presentations/ir-calendar


About Trevena
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has one approved product in the U.S., OLINVYK™ (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.   The Company also has four novel and differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, and TRV027 for acute lung injury / abnormal blood clotting in COVID-19 patients. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to treating a variety of CNS disorders.

For more information, please contact:

Investor Contact:
Daniel Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com 
(617) 430-7576

Company Contact:
Bob Yoder
SVP and Chief Business Officer
Trevena, Inc.
(610) 354-8840


Stock TRVN logo
Trevena Inc

NASDAQ:TRVN

TRVN Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

TRVN Latest News

Apr 1, 2024
Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update
Dec 28, 2023
Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise
Dec 27, 2023
Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise
Dec 4, 2023
Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting
Dec 4, 2023
Trevena Awarded OLINVYK Agreement with Premier, Inc.

TRVN Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
US
Chesterbrook

About TRVN

trevena, inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target g protein coupled receptors, or gpcrs. we are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. we have identified four biased ligand drug candidates: trv130, an fda-designated breakthrough therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; trv027 was evaluated in a phase 2b study for the treatment of acute heart failure; trv734 has completed phase 1 testing for oral treatment of acute and chronic pain; and trv250 is in preclinical development for the treatment of migraine. in addition, trevena has an early stage portfolio of drug discovery programs currently in lead optimization.